These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 16801344)

  • 1. Polyalanine and polyserine frameshift products in Huntington's disease.
    Davies JE; Rubinsztein DC
    J Med Genet; 2006 Nov; 43(11):893-6. PubMed ID: 16801344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease.
    Aldous SG; Smith EJ; Landles C; Osborne GF; Cañibano-Pico M; Nita IM; Phillips J; Zhang Y; Jin B; Hirst MB; Benn CL; Bond BC; Edelmann W; Greene JR; Bates GP
    Brain; 2024 May; 147(5):1784-1798. PubMed ID: 38387080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deleterious and protective properties of an aggregate-prone protein with a polyalanine expansion.
    Berger Z; Davies JE; Luo S; Pasco MY; Majoul I; O'Kane CJ; Rubinsztein DC
    Hum Mol Genet; 2006 Feb; 15(3):453-65. PubMed ID: 16371423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PolyQ-independent toxicity associated with novel translational products from CAG repeat expansions.
    Rudich P; Watkins S; Lamitina T
    PLoS One; 2020; 15(4):e0227464. PubMed ID: 32240172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells.
    Naphade S; Tshilenge KT; Ellerby LM
    Neurotherapeutics; 2019 Oct; 16(4):979-998. PubMed ID: 31792895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases].
    Bogomazova AN; Eremeev AV; Pozmogova GE; Lagarkova MA
    Mol Biol (Mosk); 2019; 53(6):954-967. PubMed ID: 31876275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
    Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
    Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.
    Hackam AS; Hodgson JG; Singaraja R; Zhang T; Gan L; Gutekunst CA; Hersch SM; Hayden MR
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1047-55. PubMed ID: 10434304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
    Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington's disease.
    Aviner R; Lee TT; Masto VB; Li KH; Andino R; Frydman J
    Nat Cell Biol; 2024 Jun; 26(6):892-902. PubMed ID: 38741019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mediators, environmental modulators and experience-dependent synaptic dysfunction in Huntington's disease.
    Hannan AJ
    Acta Biochim Pol; 2004; 51(2):415-30. PubMed ID: 15218539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyglutamine tracts regulate beclin 1-dependent autophagy.
    Ashkenazi A; Bento CF; Ricketts T; Vicinanza M; Siddiqi F; Pavel M; Squitieri F; Hardenberg MC; Imarisio S; Menzies FM; Rubinsztein DC
    Nature; 2017 May; 545(7652):108-111. PubMed ID: 28445460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.
    Panov AV; Burke JR; Strittmatter WJ; Greenamyre JT
    Arch Biochem Biophys; 2003 Feb; 410(1):1-6. PubMed ID: 12559971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?
    Davies SW; Beardsall K; Turmaine M; DiFiglia M; Aronin N; Bates GP
    Lancet; 1998 Jan; 351(9096):131-3. PubMed ID: 9439509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
    Yang S; Yang H; Huang L; Chen L; Qin Z; Li S; Li XJ
    Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4411-4417. PubMed ID: 32029588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects.
    Luthi-Carter R; Strand AD; Hanson SA; Kooperberg C; Schilling G; La Spada AR; Merry DE; Young AB; Ross CA; Borchelt DR; Olson JM
    Hum Mol Genet; 2002 Aug; 11(17):1927-37. PubMed ID: 12165555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.